CellCarta

09/17/2026

We're excited to share the latest installment of Let's Talk, featuring a conversation between Christopher Ung and Dr. Zhou Caicun, world-leading Chinese oncologist, lung cancer expert, and principal investigator of HARMONi-2, a phase III clinical trial evaluating Ivonescimab, a PD-L1/VEGF bispecific antibody in NSCLC.

Expect direct insights into how Dr. Zhou started working on lung cancer, the huge changes the field has undergone, the impact of Ivonescimab on clinical outcomes, and China's emerging role in therapeutic innovation.

The full talk is live now! https://buff.ly/jKKZ2fB

09/16/2026

A contingent of Team CellCarta is heading to Boston, October 6-8th for the World CB & CDx Summit.

If your team is at any stage of the CDx development process, from early biomarker work to contemplating your submission strategy, now is a great time to book a CDx Strategy Session.

We're excited to share how our fast, flexible and collaborative approach can accelerate your CDx strategy, regardless of your stage.

If you're heading to Boston, don't miss this chance to meet the team. Book a meeting here: https://buff.ly/0XJJYuT

09/15/2026

CellCarta is excited to announce the expansion of our mass cytometry services with the introduction of the CyTOF™ XT PRO from Standard BioTools at our Montreal laboratory.

What makes the CyTOF™ XT PRO so exciting for clinical trial testing?

· Improves data consistency and reproducibility through enhanced QC and calibration

· Safeguards valuable clinical samples with automated cleaning and clog detection

· Accelerates turnaround time with faster sample throughput for large cohort studies

· Supports regulated workflows and GxP testing with 21 CFR Part 11-enabled software

The CyTOF™ XT PRO represents a significant advancement in reliability and standardization, enabling CellCarta to continue delivering high-quality precision phenotyping and high-plex functional immunology for our partners’ programs.

Learn more about CellCarta's mass cytometry services here: https://buff.ly/wlQ1uAf

09/14/2026

Conference season is taking off 🚀 Will we see you at Biomarkers, CDx & Precision Medicine US in San Diego?

Don't miss the chance to meet Patrick Reese, Patrick Jackle and James Flynn, and learn how we can accelerate your precision medicine programs from early stage biomarker work to CDx commercialization with our collaborative, flexible approach.

Busy week? Book a meeting to make sure you catch the team: https://buff.ly/w3b9ON2

09/12/2026

As Autoimmune Therapies Evolve, Immune Monitoring Must Too.

Don't miss this interview with Dr. Céline Vandamme, one of our immunology experts on how advances in B-cell-depleting therapies are transforming autoimmune disease treatment, and why highly sensitive, standardized immune monitoring will be essential to support the next generation of clinical trials.

Dr. Céline Vandamme discusses how next-generation BCDTs are changing autoimmune disease treatment, and why high-sensitivity flow cytometry, standardized workflows, and multiomics approaches will be critical for monitoring immune reset.

09/10/2026

Targeted Protein Degradation (TPD) is an emerging therapeutic approach designed to selectively remove disease-relevant proteins using degrader molecules, creating new opportunities for therapeutic mechanisms of action beyond traditional inhibition.

One of the analytical challenges is accurately assessing how much of a target protein has been degraded; particularly when protein levels approach or fall below 90% of the endogenous level.

With the SCIEX 7500+ now added to CellCarta’s current mass spectrometry fleet, and its best-in-class sensitivity, we can look beyond what was previously measurable and gain greater granularity into the extent of target protein degradation.

A powerful new capability for advancing the bioanalytical characterization of next-generation protein degraders. Reach out to our team to learn how mass spec can deliver the analytical data you need: https://cellcarta.com/contact/?utm_source=facebook&utm_medium=social&utm_campaign=pc

09/09/2026

Quality immunology data isn't a nice-to-have; it's what every go/no-go decision and regulatory submission depends on.

Our immunology team delivers, with globally harmonized SOPs, CAP-accredited, CLIA-certified labs, PhD-level scientists, and cross-site quality systems. From first-in-human to routine monitoring to pivotal trials, we're ready to support your program goals.

Connect with our experts today: https://buff.ly/APgNbQd

09/03/2026

Biomarker-driven development works best when the science, strategy and regulatory approach are connected from day one. Ahead of Biomarkers US, September 23-24, in San Diego, we're highlighting how our harmonized global labs deliver consistent, regulatory-ready biomarker data across modalities. Come visit Patrick Jackle and James Flynn at our booth in San Diego to learn more.

Busy schedule? Book a meeting to make sure we catch you: https://buff.ly/TtNRVwK

08/31/2026

Need a panel tailored to your protocol's exact genomic coverage? Our team designs, validates, and operationalizes custom NGS assays across our global labs, with fully-owned genomics labs in North America, Europe, and China. Talk to us about building the right assay for your trial.

https://buff.ly/jieim7F

08/27/2026

Choosing the right biomarker and clinical testing strategy can be the difference between a promising therapy reaching patients or stalling before it gets there.

For over 25 years, CellCarta has brought scientific rigor to the full spectrum of biomarker development, from discovery through companion diagnostics.

More expertise. More confidence in your data. More certainty in your next step.

Because when your science demands more, CellCarta delivers.

https://buff.ly/9NN2uPS